Success Metrics

Active Trials

3(38%)

Phase Distribution

Ph not_applicable

13%

Ph phase_1

13%

Ph phase_3

63%

Ph phase_2

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

1(12.5%)

Phase 2Efficacy & side effects

1(12.5%)

Phase 3Large-scale testing

5(62.5%)

N/ANon-phased studies

1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(8)

Detailed Status

Not yet recruiting5

Recruiting2

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 11 (12.5%)

Phase 21 (12.5%)

Phase 35 (62.5%)

N/A1 (12.5%)

Trials by Status

active_not_recruiting113%

not_yet_recruiting563%

recruiting225%

Recent Activity

3 active trials

Showing 5 of 8

not_yet_recruitingphase_3

SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

NCT07442565

not_yet_recruitingphase_3

SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma

NCT07417735

not_yet_recruitingphase_3

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

NCT07406542

not_yet_recruitingphase_3

A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

NCT07376382

not_yet_recruitingphase_2

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

NCT07256509

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT07442565Phase 3

SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

Not Yet Recruiting

NCT07417735Phase 3

SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma

Not Yet Recruiting

NCT07406542Phase 3

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Not Yet Recruiting

NCT07376382Phase 3

A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

Not Yet Recruiting

NCT07256509Phase 2

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

Not Yet Recruiting

NCT07241936Phase 1

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors

Recruiting

NCT06927986Phase 3

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Recruiting

NCT07104877Not Applicable

A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors

Active Not Recruiting

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8